Welch & Forbes’s Milestone Pharmaceuticals MIST Stock Holding History

Welch & Forbes’s Portfolio MIST Stock Details MIST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$33.5K	Hold	25,000	–	–	﹤0.01%	387
2026 Q1	$29.8K	Buy	+25,000	New	+$43.8K	﹤0.01%	367

Other funds holding MIST

PCM

Pavaki Capital Management Pueblo, Colorado $287M AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

KCM

Kalehua Capital Management Dallas, Texas $174M AUM

LPC

Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return

Welch & Forbes's MIST Position: Q2 2026 in Review

Welch & Forbes held its Milestone Pharmaceuticals (MIST) position steady in Q2 2026 at 25,000 shares worth $33.5K. The position accounts for ﹤0.01% of the portfolio, ranked #387.

Welch & Forbes first reported a position in MIST in Q1 2026 and has held it in 2 quarters since. 78 funds tracked by Wall St. Rank hold MIST as of Q2 2026.

Welch & Forbes held 25,000 shares of Milestone Pharmaceuticals worth $33.5K as of Q2 2026.
Welch & Forbes left its Milestone Pharmaceuticals share count unchanged in Q2 2026.
Milestone Pharmaceuticals made up ﹤0.01% of Welch & Forbes's portfolio in Q2 2026, its #387 holding.
Welch & Forbes first reported a position in Milestone Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
78 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q2 2026.

Based on Welch & Forbes's 13F filing for Q2 2026, filed 30 Jul 2026.